BAR­DA bets $86M on Con­tra­Fec­t's PhI­II bid against drug-re­sis­tant Staph

Be­fore they be­came known as the Covid-19 Vac­cines Fund­ing Agency, BAR­DA de­vot­ed much of its drug de­vel­op­ment ef­forts to ad­vanc­ing drugs for a dif­fer­ent out­break …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER